Last reviewed · How we verify
Conventional Best Asthma Therapy
Conventional best asthma therapy typically combines inhaled corticosteroids with long-acting beta-2 agonists to reduce airway inflammation and improve bronchodilation.
Conventional best asthma therapy typically combines inhaled corticosteroids with long-acting beta-2 agonists to reduce airway inflammation and improve bronchodilation. Used for Persistent asthma (mild, moderate, or severe), Asthma maintenance and prevention of exacerbations.
At a glance
| Generic name | Conventional Best Asthma Therapy |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Combination therapy (inhaled corticosteroid + long-acting beta-2 agonist) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Inhaled corticosteroids suppress airway inflammation by inhibiting inflammatory mediators and immune cell recruitment, while long-acting beta-2 agonists activate beta-2 adrenergic receptors on airway smooth muscle to promote bronchodilation. This combination approach addresses both the inflammatory and bronchospasm components of asthma pathophysiology. The term 'conventional best asthma therapy' refers to the standard-of-care regimen rather than a single novel drug entity.
Approved indications
- Persistent asthma (mild, moderate, or severe)
- Asthma maintenance and prevention of exacerbations
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
Key clinical trials
- Digital Prevention of Asthma (NA)
- A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (PHASE3)
- SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma (PHASE3)
- STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma (PHASE3)
- MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults (PHASE4)
- SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults (PHASE3)
- Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults (PHASE3)
- DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional Best Asthma Therapy CI brief — competitive landscape report
- Conventional Best Asthma Therapy updates RSS · CI watch RSS
- AstraZeneca portfolio CI